⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29600843 | 0.57 | ALDH1A1 (0.38) | — | |
| SCHEMBL445256 | 0.57 | — | — | |
| SCHEMBL20787073 | 0.56 | — | — | |
| SCHEMBL469710 | 0.54 | — | — | |
| Ethylene SCHEMBL28799640 | 0.54 | — | — | |
| SCHEMBL3440738 | 0.54 | — | — | |
| SCHEMBL3572806 | 0.53 | — | — | |
| SCHEMBL11033591 | 0.53 | — | — | |
| SCHEMBL4929964 | 0.53 | — | — | |
| Hydrochloric Acid SCHEMBL2574485 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362494-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | Evonik Degussa GmbH (DE) | 2018-08-22 | — | — | EP | claimed |
| WO-2017065832-A1 | POLYURETHANE CATALYSTS FROM SULFUR BASED SALTS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2017-04-20 | — | — | WO | claimed |
| EP-2909164-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | Fermion Oy (FI) | 2015-08-26 | — | — | EP | claimed |
| WO-2014060639-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | FERMION OY (FI) | 2014-04-24 | — | — | WO | claimed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | claimed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-11147275-B2 | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi | BASF SE (DE) | 2021-10-19 | — | — | US | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20200315177-A1 | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-08 | — | — | US | disclosed |
| EP-3019541-B1 | ELECTROACTIVE POLYMERS, MANUFACTURING PROCESS THEREOF, ELECTRODE AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2018-09-19 | — | — | EP | disclosed |
| EP-3019541-A1 | ELECTROACTIVE POLYMERS, MANUFACTURING PROCESS THEREOF, ELECTRODE AND USE THEREOF | Evonik Degussa GmbH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20120171283-A1 | Liposomes Useful for Drug Delivery | IPSEN BIOPHARM LTD. (GB) | 2012-07-05 | — | — | US | disclosed |
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7767842-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA SA (FR) | 2010-08-03 | — | — | US | disclosed |
| EP-1853573-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070249565-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA S.A. (FR) | 2007-10-25 | — | — | US | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006091858-A1 | BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |